Samer Srour, MB ChB, MS, on Proof-of-Concept of Allogeneic CAR T in Renal Cell Carcinoma
The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.
“The biggest highlights from the study are that we did not see any unexpected safety signals and we have seen very encouraging results for being an early phase study at very low dose levels... This is a proof of concept that we can do something for solid tumors since there's a lot of challenges using CAR T-cell treatments."
ALLO-316, Allogene Therapeutics’ allogeneic chimeric antigen receptor (CAR) T-cell therapy, demonstrated antitumor activity with a manageable safety profile in participants with advanced or metastatic CD70+ clear cell renal cell carcinoma (ccRCC), according to updated data in the phase 1 TRAVERSE study (NCT04696731) presented by Samer Srour, MB ChB, MS, assistant professor, stem cell transplantation, MD Anderson Cancer Center, at the American Associated for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.
CGTLive™’s sister site, OncLive™, spoke with Srour to learn more about ALLO-316 and the updated data, including an overall response rate of 17% (30% in patients with confirmed CD70+ tumors) and a disease control rate of 89%; mostly mild cytokine release syndrome cases, and a single dose-limiting toxicity of grade 3 type 2 autoimmune hepatitis. He also discussed the importance of the trial as a proof-of-concept for allogeneic CAR T-cell therapy in treating solid tumors, a field that has posed many challenges to the use of traditional CAR T-cell therapies.
Click here to read more coverage of the AACR 2023 Annual Meeting.
